Naluzotan

Naluzotan

Systematic (IUPAC) name
N-(3-{4-[4-(1-cyclohexylmethanesulfonamido)butyl]piperazin-1-yl}phenyl)acetamide
Clinical data
Routes of administration	Oral
Identifiers
CAS Number	740873-06-7
ATC code	None
PubChem	CID: 11430856
ChemSpider	9605731
UNII	LQ54E5B4EW Y
Chemical data
Formula	C23H38N4O3S
Molecular mass	450.638 g/mol
SMILES O=C(Nc3cccc(N2CCN(CCCCNS(=O)(=O)CC1CCCCC1)CC2)c3)C
InChI InChI=1S/C23H38N4O3S/c1-20(28)25-22-10-7-11-23(18-22)27-16-14-26(15-17-27)13-6-5-12-24-31(29,30)19-21-8-3-2-4-9-21/h7,10-11,18,21,24H,2-6,8-9,12-17,19H2,1H3,(H,25,28) Key:SPWZXWDPAWDKQE-UHFFFAOYSA-N
(verify)

Naluzotan (INN, USAN; PRX-00023) is a serotonergic drug of the phenylpiperazine class that was under investigation by EPIX Pharmaceuticals Inc for the treatment of generalized anxiety disorder and major depressive disorder. It acts as a selective and potent 5-HT_1A receptor partial agonist, readily stimulating prolactin responses, though it has also been found to bind to and activate the σ receptor. Naluzotan was well tolerated in clinical trials, with more patients in the control group dropping out due to adverse effects than in the active group in one study. The most frequently reported side effect was headache in 15% of patients (compared to 10% for placebo). In addition, naluzotan demonstrated significant antidepressant and anxiolytic effects as per the HAM-D and MADRS and the HAM-A, respectively, in some trials, but in others it did not. In the end it was not found to be significantly superior enough to placebo and development was stopped.

See also

• Phenylpiperazine